Tonix Pharmaceuticals Holding Corp (TNXP) Stock Analysis

Verdict: WATCH (do not buy)

Market cap trading below cash balance provides downside buffer while active insider buying offsets high $100M annual cash burn.

Investment score: 51/100

Analysis as of

Is Tonix Pharmaceuticals Holding Corp stock worth reviewing? The TradeMates thesis

The model evaluates TNXP as a high-risk speculative clinical biopharmaceutical stock trading at a discount to net cash ($207.6M cash vs $201.7M market cap). Multiple insider purchases offer strong sentiment alignment, but an annual burn of $103.2M mandates a HOLD stance until Phase 3 clinical data or NDA milestones de-risk cash burn.

7-factor investment score

Tonix Pharmaceuticals Holding Corp opportunities and risks

What speaks for TNXP

What speaks against TNXP

Frequently asked questions about Tonix Pharmaceuticals Holding Corp (TNXP)

Is TNXP stock a good investment?

The TradeMates model rates Tonix Pharmaceuticals Holding Corp as WATCH (do not buy) with an investment score of 51/100. The model evaluates TNXP as a high-risk speculative clinical biopharmaceutical stock trading at a discount to net cash ($207.6M cash vs $201.7M market cap). Multiple insider purchases offer strong sentiment alignment, but an annual burn of $103.2M mandates a HOLD stance until Phase 3 clinical data or NDA milestones de-risk cash burn. This is algorithmic model output, not personal investment advice.

Is TNXP stock a buy?

The TradeMates model verdict for TNXP is WATCH (do not buy) with an investment score of 51/100. Treat this as a model signal to review, not a personal buy recommendation.